ArticleFrontiers in immunology2026
Single-cell and spatial transcriptomic profiling reveals the expression characteristics of PTPRR in epithelial cells and its potential implications in pancreatic cancer metastasis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant digestive tumor with an extremely low 5-year survival rate, and KRAS mutation is its predominant molecular characteristic. Protein tyrosine phosphatase receptor R (PTPRR) functions as a tumor suppressor in most cancers; however, its expression pattern, biological function, and regulatory mechanism in PDAC remain largely unknown. Methods: Multiple public datasets including TCGA-PAAD and GSE79668 were integrated for differential gene screening. Survival analysis, TMB evaluation, KEGG enrichment, single-cell and spatial transcriptomic analyses were performed. Results: PTPRR was significantly upregulated in PDAC tissues and almost exclusively expressed in pancreatic ductal epithelial cells, with significantly higher levels in metastatic lesions than in primary tumors. High PTPRR expression correlated with lymph node metastasis, advanced stage, and poor prognosis (Log-rank P<0.05), serving as an independent adverse prognostic factor. PTPRR-related genes were enriched in MAPK and RAS signaling. The PTPRR high-expression group exhibited higher TMB (P = 0.0035) and increased mutation frequencies of KRAS and TP53. PTPRR was highly expressed in metastatic PDAC cell lines; its overexpression promoted migration and invasion, while knockdown suppressed proliferation, migration, and invasion. At single-cell level, PTPRR-high epithelial cells showed elevated stemness and formed a specific niche with iCAFs via EDN, EGF, and PDGF signaling. In metastatic patients, PTPRR-high tumor cells were associated with an immunosuppressive microenvironment by interacting with T cells and other immune cells through TGFβ, CCL, and CXCL pathways. Conclusion: PTPRR serves as an epithelial-specific biomarker closely associated with PDAC progression. It is correlated with PDAC metastasis, potentially via regulating the MAPK pathway, interacting with iCAFs, and associating with an immunosuppressive microenvironment in a metastasis-dependent manner. KRAS mutation may underlie its functional conversion from tumor suppressor to oncogene, which remains a hypothetical mechanism. PTPRR represents a promising prognostic biomarker and potential therapeutic target for PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.